A blood test called apolipoprotein B (apoB) is significantly better at predicting who will have a heart attack or stroke than the standard cholesterol tests millions of Americans get every year. Researchers at Northwestern Medicine found that using apoB to guide cholesterol treatment would prevent more heart attacks and strokes while remaining cost-effective for the healthcare system .

Why Does apoB Testing Work Better Than Standard Cholesterol Tests?

For decades, doctors have relied on LDL cholesterol (often called "bad cholesterol") and non-HDL cholesterol measurements to decide when patients need cholesterol-lowering medications like statins. But these tests don't tell the whole story. ApoB works differently because it counts the actual number of harmful cholesterol-carrying particles in your blood, rather than just measuring cholesterol levels .

Think of it this way: LDL cholesterol measures how much cholesterol is in the blood, but apoB counts how many particles are carrying that cholesterol. More particles mean more opportunities for cholesterol to get stuck in your arteries and form dangerous plaques . This distinction matters because people with insulin resistance, obesity, or diabetes can have normal-looking LDL levels but still carry many harmful particles, putting them at higher risk than standard tests would suggest .

"ApolipoproteinB is better at identifying who is at risk, because it counts the total number of harmful particles in the blood," explained Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine.

Ciaran Kohli-Lynch, Assistant Professor of Preventive Medicine, Northwestern University Feinberg School of Medicine

What Did the Northwestern Study Actually Show?

Researchers used a computer simulation representing 250,000 U.S. adults who were eligible for statin therapy but had no existing heart disease. They compared three strategies for guiding treatment decisions: LDL cholesterol (goal below 100 mg/dL), non-HDL cholesterol (goal below 118 mg/dL), and apoB (goal below 78.7 mg/dL) .

When patients didn't reach their assigned goals, treatment was intensified first with stronger statins, then by adding another medication called ezetimibe. The model tracked outcomes over a lifetime, including heart attacks, strokes, life expectancy, quality of life, and healthcare costs .

The results were clear: apoB-guided care outperformed both LDL and non-HDL approaches. It prevented more cardiovascular events while remaining cost-effective, meaning the extra expense of the apoB test was justified by the lives saved and complications prevented .

Why Isn't apoB Testing Already Standard?

Despite strong evidence supporting apoB testing, it remains underused in routine medical practice. The main barriers are cost and convenience. Unlike standard cholesterol panels, apoB testing typically requires an additional blood test, which adds to the expense and complexity of screening .

However, the Northwestern study directly addressed this concern by asking whether the extra cost is worth it. The answer, according to their analysis, is yes. The health benefits achieved through apoB-guided treatment represent good value for healthcare payers .

How to Support Your Cardiovascular Health Today

• Know Your Numbers Early: Experts recommend getting at least one cholesterol measurement between ages 18 and 30, since cumulative cholesterol exposure in early adulthood strongly predicts cardiovascular risk decades later .
• Choose Healthier Fats: Replace saturated fats and trans fats with monounsaturated fats found in olive oil, avocados, and nuts, or polyunsaturated fats from fatty fish and plant oils. A Mediterranean-style diet showed about a 30% reduction in major cardiovascular events in landmark research .
• Increase Soluble Fiber Intake: Consuming 5 to 10 grams of soluble fiber daily (as part of 25 to 30 grams total daily fiber) may reduce LDL cholesterol by 5 to 10% .
• Add Plant Sterols to Your Diet: About 2 grams of plant sterols or stanols per day may reduce LDL cholesterol by 8 to 10% .
• Discuss Testing with Your Doctor: Ask whether apoB testing makes sense for your individual risk profile, especially if you have diabetes, obesity, or a family history of early heart disease .

What About Other Emerging Cholesterol Treatments?

Beyond apoB testing, new medications are expanding treatment options. Evolocumab (brand name Repatha), a PCSK9 inhibitor, has shown promise in reducing the risk of first major cardiovascular events in high-risk patients without known significant atherosclerosis. In a recent subgroup analysis of 3,655 patients with diabetes followed for a median of 4.8 years, evolocumab reduced the risk of heart attack, stroke, or coronary heart disease death by 31% compared with placebo .

The median achieved LDL cholesterol level with evolocumab was 44 mg/dL, compared to 105 mg/dL with standard therapy alone, demonstrating that intensive LDL lowering below what statins typically achieve can provide additional cardiovascular protection .

Additionally, researchers are testing drugs that target a different cholesterol particle called lipoprotein(a), or Lp(a). This genetically inherited particle increases the risk of atherosclerotic cardiovascular disease, aortic valve thickening, and blood clots. Unlike LDL cholesterol, Lp(a) has been resistant to traditional cholesterol medications, but new drugs like pelacarsen and lepodisiran show promise in lowering Lp(a) levels by 80% to 94% . The National Lipid Association now recommends that all adults have their Lp(a) levels measured at least once in their lifetime, with a high-risk threshold of 50 mg/dL or higher .

The Bottom Line: Why This Matters for Your Heart Health

The shift toward apoB testing and more intensive cholesterol management reflects a fundamental change in how cardiologists think about prevention. Rather than waiting for heart disease to develop, the focus is now on identifying and treating risk earlier, when interventions are most effective .

Heart disease remains the leading cause of death in the United States and a major driver of healthcare costs. When small cholesterol-carrying particles get stuck in arteries, they form plaques that narrow blood vessels and can eventually rupture, triggering heart attacks and strokes . By using better tests like apoB to identify who is truly at risk, and by treating more aggressively earlier in life, doctors can prevent many of these events before they happen.

If you're concerned about your cardiovascular risk, talk with your doctor about whether apoB testing is appropriate for you, especially if you have diabetes, obesity, or a family history of early heart disease. Combined with lifestyle changes like adopting a Mediterranean-style diet and increasing physical activity, better testing and newer medications offer real hope for preventing heart disease and stroke .